Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PSORIASIS Clear all

Conditions: Plaque Psoriasis
Interventions: PH-10 (rose bengal disodium 0.001%), Control; Drug
Lead sponsor: Provectus Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Plaque Psoriasis
Interventions: IDP-118 Lotion, IDP-118 Vehicle Lotion; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 16
States / cities: Fremont, California • Boynton Beach, Florida • North Miami Beach, Florida + 12 more

Conditions: Plaque Psoriasis
Interventions: JNJ-77242113, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 28
States / cities: Scottsdale, Arizona • Fort Smith, Arkansas • Encinitas, California + 24 more

Conditions: Psoriatic Arthritis
Interventions: Direct to patient PsA Screening Questionnaire; Other
Lead sponsor: Jessica Walsh; Other
Eligibility: 18 Years and older
Enrollment: 18,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Salt Lake City, Utah

Conditions: Psoriasis
Interventions: BMS-986165, Cyclosporine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Psoriasis, Atopic Dermatitis
Interventions: CT-100-004-A, CT-100-004-B; Device
Lead sponsor: Click Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Psoriasis
Interventions: PH-10 (0.002% Rose Bengal), PH-10 (0.005% Rose Bengal), PH-10 (0.01% Rose Bengal), Vehicle; Drug
Lead sponsor: Provectus Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Oceanside, California • Miami, Florida • New York, New York + 1 more

Conditions: Psoriasis
Interventions: Enstilar, Deucravacitinib; Drug
Lead sponsor: Psoriasis Treatment Center of Central New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: East Windsor, New Jersey

Conditions: Plaque Psoriasis
Interventions: Roflumilast foam 0.3%, Vehicle foam; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 31
States / cities: Rogers, Arkansas • Fremont, California • San Diego, California + 27 more

Conditions: Psoriasis
Interventions: BMS-986165, Placebo for BMS-986165; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 16
States / cities: Irvine, California • San Diego, California • Ocala, Florida + 13 more

Conditions: Psoriasis
Interventions: Cyclosporine; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Psoriasis, Nonalcoholic Fatty Liver Disease
Interventions: Not listed
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Psoriasis
Interventions: Online Teledermatology Care, Conventional in Office Care; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Psoriasis
Interventions: Follow up from previous treatment with MEDI-507; Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 7
States / cities: Little Rock, Arkansas • Denver, Colorado • Alpharetta, Georgia + 4 more

Conditions: Psoriasis
Interventions: Skin biopsy, Blood draw; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Psoriasis
Interventions: CP-690,550; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 2,867 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 101
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 72 more

Conditions: Plaque Psoriasis
Interventions: Placebo, ABT-874; Drug · Biological
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 1,465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 93
States / cities: Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 76 more

Conditions: Psoriasis
Interventions: CC10004; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 3
States / cities: New Brunswick, New Jersey • New York, New York

Conditions: Psoriasis Vulgaris
Interventions: CT327 0.05%, CT327 0.1%, CT327 0.5%, Placebo; Drug
Lead sponsor: Creabilis SA; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Hotsprings, Arkansas • San Ramon, California • Bay City, Michigan + 5 more

Conditions: Psoriasis Vulgaris
Interventions: LEO 90100 aerosol foam, LEO 90100 aerosol foam vehicle; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 722 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 21
States / cities: Fremont, California • Santa Monica, California • Denver, Colorado + 17 more

Conditions: Psoriasis, Plaque Psoriasis
Interventions: ARQ-151 cream 0.3%; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Mountain Brook, Alabama • Scottsdale, Arizona • Fountain Valley, California + 11 more

Conditions: Plaque Psoriasis, Psoriasis Vulgaris
Interventions: Taclonex Ointment and Hydrogel Patch, Taclonex Ointment; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Psoriasis
Interventions: Calcipotriene 0.005% Foam; Drug
Lead sponsor: Mayne Pharma International Pty Ltd; Industry
Eligibility: 12 Years to 16 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 9
States / cities: San Diego, California • Ormond Beach, Florida • Tampa, Florida + 6 more

Conditions: Atopic Dermatitis, Hidradenitis Suppurativa, Contact Dermatitis, Psoriasis
Interventions: Not listed
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Tucson, Arizona

Search by objective public record fields.

Topical PH-10 Aqueous Hydrogel and Photodynamic Therapy for Psoriasis

Safety and Efficacy of IDP-118 in Participants With Plaque Psoriasis

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

Psoriatic Arthritis D2P Screening

An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants

An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis

Randomized Study of PH-10 for Psoriasis

Combination of Sotyktu and Enstilar for Plaque Psoriasis

Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis

Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

The Effectiveness of Lower Cyclosporine Doses for Psoriasis

A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis

Evaluation of Clinical Outcomes in an Online Teledermatology Model for the Management of Psoriasis

Long-Term Follow-Up Study of Psoriasis Patients

Single Cell Genomics of Psoriatic Skin

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis

Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris

LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)

Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis

Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis

Linking Epidermal Barrier Function With Anti-Oxidant Defense Mechanisms in Skin Conditions